最新一期《新英格兰医学杂志》[NEJM,2013,368(8):709-718]报道的两项临床试验结果验证了Boehringer Ingelheim(BI)公司开发上市的抗凝新药口服凝血酶抑制剂达比加群酯(dabigatran etexilate,Pradaxa)可有效安全地长期用于预防静脉血栓栓塞[VTE,包括深静脉血栓形成(DVT)和肺栓塞(PE)]的复发。这两项名为RE-MEDY和RE-SONATE的双盲、随机临床试验旨在考察达比加群 The results of two clinical trials reported in the latest issue of the New England Journal of Medicine [NEJM, 2013, 368 (8): 709-718] validate the new anticoagulant oral thrombin inhibitor developed by Boehringer Ingelheim (BI) Dabigatran etexilate (Pradaxa) is a long-term effective and safe regimen for preventing the recurrence of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). The two double-blind, randomized clinical trials, RE-MEDY and RE-SONATE, aimed to examine dabigatran